Why did Hanmi get caught in dilemma?
Hanmi Pharm gets in the focus of controversy as being associated with the technology export of an antibody of KRW 1 trillion with Genentech while having issues with Boehringer Ingelheim which decided to return the license of ‘olmutinib(Korean product name: Olita)’ and the timing of the announceme...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
